Rep. Marjorie Taylor Greene Buys Novo Nordisk A/S (NYSE:NVO) Shares

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on October 20th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on October 15th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 10/15/2025.
• Purchased $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 10/15/2025.
• Purchased $1,001 – $15,000 in shares of Exelon (NASDAQ:EXC) on 10/15/2025.
• Purchased $1,001 – $15,000 in shares of iShares Bitcoin Trust ETF (NASDAQ:IBIT) on 10/15/2025.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 10/15/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of United Parcel Service (NYSE:UPS) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of iShares Bitcoin Trust ETF (NASDAQ:IBIT) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 9/11/2025.
• Purchased $1,001 – $15,000 in shares of iShares Bitcoin Trust ETF (NASDAQ:IBIT) on 9/11/2025.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $53.37 on Thursday. The business’s 50-day moving average is $56.51 and its two-hundred day moving average is $62.52. The company has a market capitalization of $238.29 billion, a P/E ratio of 14.66, a P/E/G ratio of 2.49 and a beta of 0.68. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $116.43.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were given a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 22.53%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on NVO. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Morgan Stanley cut Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and dropped their target price for the company from $59.00 to $47.00 in a research report on Monday, September 29th. TD Cowen decreased their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, August 19th. UBS Group lowered shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Finally, Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $76.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Jennison Associates LLC lifted its stake in Novo Nordisk A/S by 0.3% in the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after purchasing an additional 63,341 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock worth $867,998,000 after purchasing an additional 187,789 shares in the last quarter. Kingstone Capital Partners Texas LLC raised its position in shares of Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after buying an additional 10,001,898 shares during the period. Folketrygdfondet raised its position in shares of Novo Nordisk A/S by 6.9% during the 1st quarter. Folketrygdfondet now owns 9,521,912 shares of the company’s stock valued at $661,202,000 after buying an additional 617,974 shares during the period. Finally, Sustainable Growth Advisers LP raised its position in shares of Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after buying an additional 649,390 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia’s 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 14th Congressional District. She declared candidacy for the 2026 election.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.